By vgreene, 27 September, 2017 Epilepsy. There's insufficient/no evidence [I/N] for effectiveness of cannabinoids, per NAS.1 AAN2 concluded that data on cannabinoids to ↓ sz frequency are insufficient
By vgreene, 27 September, 2017 Depression in MS. Evidence for ineffectiveness of nabiximols, donabinol, nabilone is limited [L] for ↓ depressive sx in MS, per NAS1
By vgreene, 27 September, 2017 Sleep disturbance in MS. Evidence for effectiveness of cannabinoids (primarily nabiximols) for improving short-term sleep outcomes is moderate [M], per NAS1
By vgreene, 27 September, 2017 Bladder dysfxn in MS. Nabiximols is probably effective for ↓ # of bladder voids/day @ 10wk, but is of unknown efficacy for ↓ overall bladder sx (conflicting studies); THC and oral cannabis extract are probably ineffective for bladder complaints;
By vgreene, 27 September, 2017 Tremor in MS. THC and oral cannabis extract are probably ineffective; nabiximols is possibly ineffective, per AAN2
By vgreene, 27 September, 2017 Central pain or painful spasms in MS. Oral cannabis extract is effective for ↓ central pain, and THC or nabiximols are probably effective for MS-related pain or painful spasms; however, smoked marijuana is of unclear efficacy for ↓ pain, per AAN
By vgreene, 27 September, 2017 MS spasticity. Evidence for effectiveness of oral cannabinoids is conclusive or substantial [C] [S] for improving pt-reported spasticity sx, and is limited [L] for clinician-measured spasticity, per NAS.1 AAN2 concluded oral cannabis extract is establishe
By vgreene, 26 September, 2017 Depression in chronic pain pts Limited evidence L that nabilone no longer available in the U S nabiximols and dronabinol are ineffective for darr depressive sx in chronic pain pts 1
By vgreene, 26 September, 2017 Sleep disturbance due to fibromyalgia or chronic pain Moderate evidence M that cannabinoids primarily nabiximols improve short term sleep outcomes 1
